you are viewing a single comment's thread.
I guess you missed the part about the one time charge of $57 million causing the 3Q loss.
KALYDECO, KALYDECO, KALYDECO. Incivek decline is a known factor. Pipeline is longterm plus, KALYDECO is the driving factor here. This baby could double. Then takeovers come into play.
wake me when the takeovers are in play.